270 related articles for article (PubMed ID: 16215614)
41. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
42. Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: autocrine/paracrine feedback inhibition.
Mantione KJ; Cadet P; Zhu W; Kream RM; Sheehan M; Fricchione GL; Goumon Y; Esch T; Stefano GB
Addict Biol; 2008 Mar; 13(1):118-23. PubMed ID: 17573783
[TBL] [Abstract][Full Text] [Related]
43. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
Gallantine EL; Meert TF
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
[TBL] [Abstract][Full Text] [Related]
44. Overview of genetic analysis of human opioid receptors.
Spampinato SM
Methods Mol Biol; 2015; 1230():3-12. PubMed ID: 25293312
[TBL] [Abstract][Full Text] [Related]
45. Pain polymorphisms and opioids: An evidence based review.
Vieira CMP; Fragoso RM; Pereira D; Medeiros R
Mol Med Rep; 2019 Mar; 19(3):1423-1434. PubMed ID: 30592275
[TBL] [Abstract][Full Text] [Related]
46. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
47. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
48. How does morphine work?
Iversen LL
Nature; 1996 Oct; 383(6603):759-60. PubMed ID: 8892994
[No Abstract] [Full Text] [Related]
49. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype.
Matic M; Simons SH; van Lingen RA; van Rosmalen J; Elens L; de Wildt SN; Tibboel D; van Schaik RH
Pharmacogenomics; 2014 Jul; 15(10):1287-95. PubMed ID: 25155931
[TBL] [Abstract][Full Text] [Related]
50. [M1-OPIOID RECEPTOR AND CATECHOL-O-METILTRANSFERASE GENES POLYMORPHISM EFFECTS ON PERIOPERATIVE PSYCHOLOGICAL CONDITION OF THE PATIENTS AND THE EFFECTIVENESS OF POSTOPERATIVE ANALGESIA WITH OPIOIDS].
Potapov AL; Boiarkina AV
Anesteziol Reanimatol; 2015; 60(3):48-51. PubMed ID: 26415297
[TBL] [Abstract][Full Text] [Related]
51. The molecular perspective: morphine.
Goodsell DS
Oncologist; 2004; 9(6):717-8. PubMed ID: 15561815
[No Abstract] [Full Text] [Related]
52. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
[TBL] [Abstract][Full Text] [Related]
53. Intracisternal A-particle element in the 3' noncoding region of the mu-opioid receptor gene in CXBK mice: a new genetic mechanism underlying differences in opioid sensitivity.
Han W; Kasai S; Hata H; Takahashi T; Takamatsu Y; Yamamoto H; Uhl GR; Sora I; Ikeda K
Pharmacogenet Genomics; 2006 Jun; 16(6):451-60. PubMed ID: 16708053
[TBL] [Abstract][Full Text] [Related]
54. Genetic profile and cancer-related pain: a tale from two outlier cases with bone metastatic disease.
Oliveira A; Dinis-Oliveira RJ; Nogueira A; Azevedo AS; Gonçalves F; Silva P; Carvalho F; Medeiros R
Pain Med; 2014 Apr; 15(4):710-2. PubMed ID: 24330486
[No Abstract] [Full Text] [Related]
55. Opioid pharmacology.
Trescot AM; Datta S; Lee M; Hansen H
Pain Physician; 2008 Mar; 11(2 Suppl):S133-53. PubMed ID: 18443637
[TBL] [Abstract][Full Text] [Related]
56. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
57. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
Owusu Obeng A; Hamadeh I; Smith M
Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
[TBL] [Abstract][Full Text] [Related]
58. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
59. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.
Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
Peckham EM; Traynor JR
J Pharmacol Exp Ther; 2006 Mar; 316(3):1195-201. PubMed ID: 16291875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
